Piper Jaffray analyst Danielle Brill downgraded GlycoMimetics to Neutral from Overweight and cut her price target for the shares to $6 from $20. The stock closed Friday down 12c to $9.13. Rivipansel failed to meet both primary and secondary endpoints in the pivotal Phase 3 sickle cell disease trial, Brill tells investors in a research note. "It hurts to admit, but we called this one completely wrong," admits the analyst. While Brill thinks it's premature to write off GlycoMimetics' uproleselan in acute myeloid leukemia, she does see the program as higher risk following the failure of rivipansel.